

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lymphoma	Not applicable	<p>A study in mice suggests that CpG oligonucleotides can boost the CD8⁺ T cell response and help prevent lymphoma relapse. In a mouse model of lymphoma, CpG plus a mAb reduced tumor growth and increased survival times compared with either compound alone or saline control. The combination also prevented the emergence of tumors from cells that escaped the original mAb-based therapy. CpG oligonucleotides are being evaluated in a clinical trial as a cancer vaccine adjuvant.</p> <p>SciBX 2(39); doi:10.1038/scibx.2009.1469 Published online Oct. 8, 2009</p>	Work unpatented; available for licensing	<p>Varghese, B. <i>et al. Blood</i>; published online Sept. 17, 2009; doi:10.1182/blood-2009-05-223263</p> <p>Contact: Ronald Levy, Stanford University School of Medicine, Stanford, Calif. e-mail: levy@stanford.edu</p>